Long-term effect of sitagliptin on endothelial function in type 2 diabetes: A sub-analysis of the PROLOGUE study

for the PROLOGUE Study Investigators

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: As a sub-analysis of the PROLOGUE study, we evaluated the long-term effect of sitagliptin, a dipeptidyl peptidase 4 inhibitor, on endothelial function in the conduit brachial artery in patients with type 2 diabetes. Methods: In the PROLOGUE study, patients were randomly assigned to either add-on sitagliptin treatment (sitagliptin group) or continued conventional antihyperglycemic treatment (conventional group). Among the 463 participants in the PROLOGUE study, FMD was measured in 17 patients in the sitagliptin group and 18 patients in the conventional group at the beginning and after 12 and 24 months of treatment. Results: HbA1c levels were significantly decreased after 12 and 24 months of treatment compared to baseline values in both groups (7.0 ± 0.4 vs. 6.6 ± 0.3 and 6.6 ± 0.4 % in the sitagliptin group; 7.0 ± 0.6 vs. 6.6 ± 0.7 and 6.6 ± 0.7 % in the conventional group; P < 0.05, respectively). There was no significant difference between FMD values at baseline and after 12 and 24 months in the sitagliptin group (4.3 ± 2.6 vs. 4.4 ± 2.1 and 4.4 ± 2.3 %, P = 1.0, respectively). Although FMD had a tendency to increase from 4.3 ± 2.4 % at baseline to 5.2 ± 1.9 % after 12 months and 5.1 ± 2.2 % after 24 months in the conventional group, there was no significant difference between FMD values at baseline and after 12 and 24 months (P = 0.36 and 0.33, respectively). Conclusions: Add-on sitagliptin to conventional antihyperglycemic drugs in patients with type 2 diabetes did not alter endothelial function in the conduit brachial artery measured by FMD during a 2-year study period. Sitagliptin may be used without concern for an adverse effect on endothelial function in patients with type 2 diabetes. Trial registration: University hospital Medical Information Network (UMIN) Center: ID UMIN000004490

Original languageEnglish
Article number134
JournalCardiovascular Diabetology
Volume15
Issue number1
DOIs
Publication statusPublished - 13-09-2016

Fingerprint

Type 2 Diabetes Mellitus
Brachial Artery
Hypoglycemic Agents
Dipeptidyl-Peptidase IV Inhibitors
Information Centers
Information Services
Sitagliptin Phosphate
Therapeutics
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Cite this

@article{b791100221994d32bbfba5d8a164c01f,
title = "Long-term effect of sitagliptin on endothelial function in type 2 diabetes: A sub-analysis of the PROLOGUE study",
abstract = "Background: As a sub-analysis of the PROLOGUE study, we evaluated the long-term effect of sitagliptin, a dipeptidyl peptidase 4 inhibitor, on endothelial function in the conduit brachial artery in patients with type 2 diabetes. Methods: In the PROLOGUE study, patients were randomly assigned to either add-on sitagliptin treatment (sitagliptin group) or continued conventional antihyperglycemic treatment (conventional group). Among the 463 participants in the PROLOGUE study, FMD was measured in 17 patients in the sitagliptin group and 18 patients in the conventional group at the beginning and after 12 and 24 months of treatment. Results: HbA1c levels were significantly decreased after 12 and 24 months of treatment compared to baseline values in both groups (7.0 ± 0.4 vs. 6.6 ± 0.3 and 6.6 ± 0.4 {\%} in the sitagliptin group; 7.0 ± 0.6 vs. 6.6 ± 0.7 and 6.6 ± 0.7 {\%} in the conventional group; P < 0.05, respectively). There was no significant difference between FMD values at baseline and after 12 and 24 months in the sitagliptin group (4.3 ± 2.6 vs. 4.4 ± 2.1 and 4.4 ± 2.3 {\%}, P = 1.0, respectively). Although FMD had a tendency to increase from 4.3 ± 2.4 {\%} at baseline to 5.2 ± 1.9 {\%} after 12 months and 5.1 ± 2.2 {\%} after 24 months in the conventional group, there was no significant difference between FMD values at baseline and after 12 and 24 months (P = 0.36 and 0.33, respectively). Conclusions: Add-on sitagliptin to conventional antihyperglycemic drugs in patients with type 2 diabetes did not alter endothelial function in the conduit brachial artery measured by FMD during a 2-year study period. Sitagliptin may be used without concern for an adverse effect on endothelial function in patients with type 2 diabetes. Trial registration: University hospital Medical Information Network (UMIN) Center: ID UMIN000004490",
author = "{for the PROLOGUE Study Investigators} and Tatsuya Maruhashi and Yukihito Higashi and Yasuki Kihara and Hirotsugu Yamada and Masataka Sata and Shinichiro Ueda and Masato Odawara and Yasuo Terauchi and Kazuoki Dai and Jun Ohno and Masato Iida and Hiroaki Sano and Hirofumi Tomiyama and Teruo Inoue and Atsushi Tanaka and Toyoaki Murohara and Koichi Node and Masayoshi Ajioka and Toru Aoyama and Tetsuya Babazono and Bando, {Yasuko K.} and Hiroyuki Daida and Jun Fukui and Kumiko Hamano and Shigemasa Hashimoto and Kazunori Hayashi and Tsutomu Hirano and Hideki Horibe and Kazuo Ibaraki and Takako Iino and Kenji Iino and Hiroshi Ito and Yutaka Ishibashi and Ishiguro, {Yuko S.} and Takanori Yasu and Masaharu Ishihara and Ryoji Ishiki and Tomoko Ishizu and Masaaki Ito and Yoshito Iwama and Hideo Izawa and Kohei Kaku and Haruo Kamiya and Kenshi Kan and Naoki Kashihara and Akira Kimura and Ichiro Kishimoto and Kazuo Kitagawa and Masafumi Kitakaze and Tomoki Kitano",
year = "2016",
month = "9",
day = "13",
doi = "10.1186/s12933-016-0438-x",
language = "English",
volume = "15",
journal = "Cardiovascular Diabetology",
issn = "1475-2840",
publisher = "BioMed Central",
number = "1",

}

Long-term effect of sitagliptin on endothelial function in type 2 diabetes : A sub-analysis of the PROLOGUE study. / for the PROLOGUE Study Investigators.

In: Cardiovascular Diabetology, Vol. 15, No. 1, 134, 13.09.2016.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Long-term effect of sitagliptin on endothelial function in type 2 diabetes

T2 - A sub-analysis of the PROLOGUE study

AU - for the PROLOGUE Study Investigators

AU - Maruhashi, Tatsuya

AU - Higashi, Yukihito

AU - Kihara, Yasuki

AU - Yamada, Hirotsugu

AU - Sata, Masataka

AU - Ueda, Shinichiro

AU - Odawara, Masato

AU - Terauchi, Yasuo

AU - Dai, Kazuoki

AU - Ohno, Jun

AU - Iida, Masato

AU - Sano, Hiroaki

AU - Tomiyama, Hirofumi

AU - Inoue, Teruo

AU - Tanaka, Atsushi

AU - Murohara, Toyoaki

AU - Node, Koichi

AU - Ajioka, Masayoshi

AU - Aoyama, Toru

AU - Babazono, Tetsuya

AU - Bando, Yasuko K.

AU - Daida, Hiroyuki

AU - Fukui, Jun

AU - Hamano, Kumiko

AU - Hashimoto, Shigemasa

AU - Hayashi, Kazunori

AU - Hirano, Tsutomu

AU - Horibe, Hideki

AU - Ibaraki, Kazuo

AU - Iino, Takako

AU - Iino, Kenji

AU - Ito, Hiroshi

AU - Ishibashi, Yutaka

AU - Ishiguro, Yuko S.

AU - Yasu, Takanori

AU - Ishihara, Masaharu

AU - Ishiki, Ryoji

AU - Ishizu, Tomoko

AU - Ito, Masaaki

AU - Iwama, Yoshito

AU - Izawa, Hideo

AU - Kaku, Kohei

AU - Kamiya, Haruo

AU - Kan, Kenshi

AU - Kashihara, Naoki

AU - Kimura, Akira

AU - Kishimoto, Ichiro

AU - Kitagawa, Kazuo

AU - Kitakaze, Masafumi

AU - Kitano, Tomoki

PY - 2016/9/13

Y1 - 2016/9/13

N2 - Background: As a sub-analysis of the PROLOGUE study, we evaluated the long-term effect of sitagliptin, a dipeptidyl peptidase 4 inhibitor, on endothelial function in the conduit brachial artery in patients with type 2 diabetes. Methods: In the PROLOGUE study, patients were randomly assigned to either add-on sitagliptin treatment (sitagliptin group) or continued conventional antihyperglycemic treatment (conventional group). Among the 463 participants in the PROLOGUE study, FMD was measured in 17 patients in the sitagliptin group and 18 patients in the conventional group at the beginning and after 12 and 24 months of treatment. Results: HbA1c levels were significantly decreased after 12 and 24 months of treatment compared to baseline values in both groups (7.0 ± 0.4 vs. 6.6 ± 0.3 and 6.6 ± 0.4 % in the sitagliptin group; 7.0 ± 0.6 vs. 6.6 ± 0.7 and 6.6 ± 0.7 % in the conventional group; P < 0.05, respectively). There was no significant difference between FMD values at baseline and after 12 and 24 months in the sitagliptin group (4.3 ± 2.6 vs. 4.4 ± 2.1 and 4.4 ± 2.3 %, P = 1.0, respectively). Although FMD had a tendency to increase from 4.3 ± 2.4 % at baseline to 5.2 ± 1.9 % after 12 months and 5.1 ± 2.2 % after 24 months in the conventional group, there was no significant difference between FMD values at baseline and after 12 and 24 months (P = 0.36 and 0.33, respectively). Conclusions: Add-on sitagliptin to conventional antihyperglycemic drugs in patients with type 2 diabetes did not alter endothelial function in the conduit brachial artery measured by FMD during a 2-year study period. Sitagliptin may be used without concern for an adverse effect on endothelial function in patients with type 2 diabetes. Trial registration: University hospital Medical Information Network (UMIN) Center: ID UMIN000004490

AB - Background: As a sub-analysis of the PROLOGUE study, we evaluated the long-term effect of sitagliptin, a dipeptidyl peptidase 4 inhibitor, on endothelial function in the conduit brachial artery in patients with type 2 diabetes. Methods: In the PROLOGUE study, patients were randomly assigned to either add-on sitagliptin treatment (sitagliptin group) or continued conventional antihyperglycemic treatment (conventional group). Among the 463 participants in the PROLOGUE study, FMD was measured in 17 patients in the sitagliptin group and 18 patients in the conventional group at the beginning and after 12 and 24 months of treatment. Results: HbA1c levels were significantly decreased after 12 and 24 months of treatment compared to baseline values in both groups (7.0 ± 0.4 vs. 6.6 ± 0.3 and 6.6 ± 0.4 % in the sitagliptin group; 7.0 ± 0.6 vs. 6.6 ± 0.7 and 6.6 ± 0.7 % in the conventional group; P < 0.05, respectively). There was no significant difference between FMD values at baseline and after 12 and 24 months in the sitagliptin group (4.3 ± 2.6 vs. 4.4 ± 2.1 and 4.4 ± 2.3 %, P = 1.0, respectively). Although FMD had a tendency to increase from 4.3 ± 2.4 % at baseline to 5.2 ± 1.9 % after 12 months and 5.1 ± 2.2 % after 24 months in the conventional group, there was no significant difference between FMD values at baseline and after 12 and 24 months (P = 0.36 and 0.33, respectively). Conclusions: Add-on sitagliptin to conventional antihyperglycemic drugs in patients with type 2 diabetes did not alter endothelial function in the conduit brachial artery measured by FMD during a 2-year study period. Sitagliptin may be used without concern for an adverse effect on endothelial function in patients with type 2 diabetes. Trial registration: University hospital Medical Information Network (UMIN) Center: ID UMIN000004490

UR - http://www.scopus.com/inward/record.url?scp=84992361845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992361845&partnerID=8YFLogxK

U2 - 10.1186/s12933-016-0438-x

DO - 10.1186/s12933-016-0438-x

M3 - Article

C2 - 27624168

AN - SCOPUS:84992361845

VL - 15

JO - Cardiovascular Diabetology

JF - Cardiovascular Diabetology

SN - 1475-2840

IS - 1

M1 - 134

ER -